Paper Details

  1. Home
  2. Paper Details

Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.

Author: DengChao, HanMei, LianJiamei, SuYueqing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Olanzapine, a commonly used antipsychotic drug, is associated with metabolic disorders. It is a potent antagonist of the M3 acetylcholine muscarinic receptor (M3R), and downregulation of the hepatic M3R-AMPKα signaling pathway is implicated in these metabolic disturbances.
Paper Details　
Original Abstract of the Article :
Olanzapine is one of the most commonly used antipsychotic drugs; however, its metabolic disorders are the main obstacle in the clinic. Olanzapine is a potent antagonist of the M3 acetylcholine muscarinic receptor (M3R), while the downregulated hepatic M3R-AMPKα signalling pathway is involved in meta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/02698811211050549

データ提供：米国国立医学図書館（NLM）

Olanzapine-Induced Metabolic Disorders: A Camel's Search for Solutions

Olanzapine, a commonly used antipsychotic medication, can have significant metabolic side effects, impacting patients' overall health. This study investigates the mechanisms underlying these metabolic disorders and explores the potential of cevimeline, a cholinergic agonist, to mitigate these adverse effects. The authors delve into the role of the M3 muscarinic receptor (M3R) and the AMPKα signaling pathway in olanzapine-induced metabolic dysfunction.

A Potential Oasis: Cevimeline for Mitigating Olanzapine-Induced Metabolic Disorders

This study, like a camel seeking a respite from the harsh desert conditions, highlights the potential of cevimeline as a therapeutic agent for mitigating olanzapine-induced metabolic disorders. The authors demonstrate that cevimeline can modulate the hepatic M3R-AMPKα signaling pathway, potentially reducing the metabolic side effects associated with olanzapine treatment. The research provides a promising lead for developing strategies to manage these adverse effects and improve patient outcomes.

Health Implications and Lifestyle Applications

Individuals taking olanzapine should be aware of the potential metabolic side effects. It's important to discuss these risks with healthcare professionals and monitor metabolic health parameters closely. Maintaining a healthy lifestyle, including regular exercise and a balanced diet, can also contribute to managing metabolic health and mitigating the risks associated with olanzapine treatment.

Dr.Camel's Conclusion

The desert of olanzapine-induced metabolic disorders can be a challenging landscape for patients. This study offers a glimmer of hope in the form of cevimeline, a potential therapeutic agent for mitigating these adverse effects. The research provides a roadmap for future studies and underscores the importance of ongoing research to develop effective strategies for managing the metabolic side effects of antipsychotic medications.

Date :
  1. Date Completed 2022-03-03
  2. Date Revised 2022-03-03
Further Info :

Pubmed ID

34694173

DOI: Digital Object Identifier

10.1177/02698811211050549

Related Literature

Article Analysis
・Side Effects of cevimeline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.